Complete Wegovy vs Mounjaro Dosage Comparison & Switch Guide
Wegovy vs Mounjaro Dosage Chart: Understanding the Switch & Save Opportunity
When comparing Wegovy vs Mounjaro dosage charts, the fundamental difference lies in their escalation schedules and mechanisms of action. Wegovy (semaglutide) follows a 5-stage dose escalation over 16 weeks, starting at 0.25mg and reaching the maintenance dose of 2.4mg, while Mounjaro (tirzepatide) uses a 4-stage escalation reaching 15mg maximum. The switching opportunity becomes particularly attractive when considering that Wegovy operates as a GLP-1 receptor agonist, while Mounjaro is a dual GIP and GLP-1 receptor agonist, offering patients different therapeutic profiles to explore with their prescriber.
The "Switch & Save" advantage becomes evident when examining the structured approach both medications require. Patients switching from Mounjaro to Wegovy often find the longer escalation period more tolerable, with smaller dose increments potentially reducing gastrointestinal side effects. Your prescriber will determine the appropriate starting dose when switching, which may not always begin at 0.25mg depending on your current Mounjaro dose and individual response. Both treatments are available through EverydayMeds' streamlined service, ensuring continuity of care during your transition period.
Wegovy vs Mounjaro Dosage Chart: Pricing Analysis and Bundle Savings
The cost comparison in our Wegovy vs Mounjaro dosage chart reveals significant potential savings for patients considering a switch. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. New customers benefit from code FIRST40, while returning patients use DOSE25, both applied at checkout to reach these final prices. Our Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg) at £169.99, provide convenient dose progression without multiple orders.
For patients seeking extended supply security, our Step-Up bundles offer comprehensive coverage through escalation phases. The Intro Trio (0.25mg, 0.5mg & 1mg) at £299.99 covers the first 12 weeks of treatment, while the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 suits those transitioning from Mounjaro at higher equivalent doses. Maintenance patients benefit from our Ultimate Stability Trio (three 2.4mg pens) at £649.99, providing three months of consistent supply with assured cold-chain delivery and storage.
Clinical Evidence Supporting Wegovy vs Mounjaro Dosage Chart Decisions
The clinical foundation for our Wegovy vs Mounjaro dosage chart comparison stems from robust trial programmes with different endpoints and populations. In the STEP trials, patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks (Wilding et al., NEJM, 2021). The dose escalation protocol proved essential for tolerability, with the structured 16-week escalation significantly reducing discontinuation rates compared to faster titration schedules.
When comparing clinical profiles, both medications demonstrate efficacy as prescription-only medicines requiring careful medical supervision. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events with semaglutide, adding another dimension to prescriber decision-making when evaluating patient switches. Individual response varies significantly, making the availability of both options through EverydayMeds particularly valuable for optimising treatment outcomes.
How Wegovy Works: GLP-1 Mechanism in Dosage Chart Context
Understanding Wegovy's mechanism is crucial when interpreting our Wegovy vs Mounjaro dosage chart, as it explains why the dose escalation follows its specific pattern. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone controlling appetite and satiety. The medication works primarily in the brain's appetite centres, reducing hunger signals and promoting feelings of fullness after smaller meals. This mechanism requires gradual dose increases to allow the body's systems to adapt, preventing the gastrointestinal side effects that can occur with rapid titration. The 4-week intervals between dose increases in our dosage chart reflect this physiological adaptation period, ensuring optimal tolerability while building therapeutic effectiveness.
Ordering Process: Seamless Wegovy vs Mounjaro Dosage Chart Transitions
Our streamlined ordering process makes implementing your Wegovy vs Mounjaro dosage chart transition straightforward and medically supervised. The journey begins with our 3-minute online clinical assessment, specifically designed to capture your current medication history, including Mounjaro dosing and any experienced side effects. Our prescribers review all switching requests with particular attention to dose equivalents and timing, ensuring safe transitions between treatments. Standard prescriber review takes 3 working days, though our express service offers 24-hour turnaround for urgent switching requirements. Once approved, your Wegovy pens are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transit to preserve medication integrity.
Storage Advantages: Wegovy vs Mounjaro Dosage Chart Practical Considerations
The storage comparison in our Wegovy vs Mounjaro dosage chart reveals a significant practical advantage for Wegovy users. While both medications require refrigeration at 2-8°C before first use, Wegovy offers superior room temperature stability once removed from the fridge. Wegovy pens remain stable for up to 6 weeks at room temperature below 30°C, compared to Mounjaro's 21-day limit, making Wegovy more suitable for patients with travel commitments or irregular schedules. The FlexTouch pen delivery system used by Wegovy provides precise dose delivery across all five escalation stages, from 0.25mg through to the 2.4mg maintenance dose. This extended stability reduces medication waste and provides greater flexibility for patients managing complex lifestyles while maintaining their weight management programme.
Switching Strategies: Advanced Wegovy vs Mounjaro Dosage Chart Guidance
The switching decision within our Wegovy vs Mounjaro dosage chart requires individualised assessment based on your current tirzepatide dose and treatment response. Patients switching from Mounjaro 2.5mg may start Wegovy at 0.5mg rather than 0.25mg, while those on higher Mounjaro doses might begin at 1mg, though this determination rests entirely with your prescriber. The transition typically involves a washout period, with the exact timing dependent on your last Mounjaro injection and individual clearance factors.
Cost considerations often drive switching decisions, particularly when comparing long-term maintenance costs between the medications. Our Consistency bundles provide ongoing supply security, with the Consistency 2.4mg bundle (two maintenance pens) at £419.99 offering two months of stable treatment. The switching process includes comprehensive support from our clinical team at GPhC #9012878, ensuring continuity of care throughout your transition period.
Complete Your Wegovy vs Mounjaro Dosage Chart Switch Today
Take control of your weight management journey by exploring the switching opportunity our Wegovy vs Mounjaro dosage chart comparison reveals. With new customer code FIRST40 and returning customer code DOSE25 applied at checkout, you can begin your Wegovy trial from £79.99 with complete confidence in our prescription-only medicine service. Our clinical team stands ready to guide your transition, ensuring optimal dosing and timing for your individual circumstances. Visit our weight loss collection to start your clinical assessment and discover how switching to Wegovy might enhance your treatment experience. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which option best suits your needs alongside a reduced-calorie diet and increased physical activity.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
